Explore the exciting world of Pfizer (NYSE: PFE) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...
24/7 Wall St. on MSN
Abbott Labs vs. Pfizer: Which discounted healthcare titan screens as the bigger value trap?
Quick ReadAbbott (ABT) is down 23% year to date with insiders buying near $92; Pfizer (PFE) pairs a 7% yield with a ...
Pfizer (NYSE: PFE) was founded in 1849. That makes the company well over 100 years old. Not many companies have managed to survive as long as Pfizer has, especially in an industry as highly technical ...
There are actually two factors to consider in the current drawdown. The first is the massive stock price spike that occurred during the coronavirus pandemic. Pfizer was one of a small number of ...
Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...
Late in 2023 I believed that the potential was still there in the case of Pfizer (PFE) after another setback in the pipeline. To see where Pfizer comes from, we really have to create some perspective, ...
Pfizer’s PFE 2024 revenue reached $63.6 billion, near the high end of its $61 billion-$64 billion guidance range. Management reaffirmed expectations for 2025 revenue of $61 billion-$64 billion and ...
Pfizer PFE reported stronger third-quarter results than we anticipated, largely due to significantly higher sales of covid-19 treatment Paxlovid, which also drove management to increase its top- and ...
NEW YORK, Oct 22 (Reuters) - Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's (PFE.N), opens new tab board needs to hold management accountable for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results